Press
Dompé Further Elevates Commitment to Ophthalmics with Industry-Leading Hires
April 26, 2022
Dompé announces first patient enrolled in Phase 3 trial of cenegermin in patients with severe Sjögren's-related dry eye disease
February 10, 2022
Dompé to expand Commercial Operations for Oxervate to Canada
October 11, 2021
Dompé Announces Activation of U.S. Clinical Trial Sites for Phase 3 Study of Reparixin, an Oral Investigational CXCR1/CXCR2 Inhibitor, in Hospitalized Patients with Severe COVID-19 Pneumonia
June 3, 2021
EXSCALATE4COV: Italian Medicines Agency (AIFA) authorizes Raloxifene Clinical Trial for Paucisymptomatic Covid-19 Patients treated at Home and in Medical Facilities
October 27, 2020
Dompé Appoints New Global Biotech Head
September 21, 2020
EU-supported Private-Public Consortium Exscalate4CoV : Raloxifene proposed for clinical trials after tests show it inhibits SARS-CoV-2
June 18, 2020
Dompé Presents Phase II Clinical Trial Results for Ladarixin in New-Onset Type 1 Diabetes at the American Diabetes Association’s Scientific Sessions
June 15, 2020
Dompé to Present Phase II Clinical Data for Ladarixin in New-Onset Type 1 Diabetes (T1D) at the American Diabetes Association’s Scientific Sessions
June 8, 2020
AIFA Announces Italian Authorization of Phase 2/3 Clinical Trial of Dompé’s Reparixin for the Treatment of Severe Patients with COVID-19 Pneumonia
May 12, 2020